These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29463555)

  • 1. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
    J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P; Foglizzo V; Harada G; Repetto M; Kulick A; de Stanchina E; de Marchena M; Auwardt S; Sayed Ahmed S; Bremer NV; Yang SR; Feng Y; Zhou C; Kong N; Liang R; Xu H; Zhang B; Bardelli A; Toska E; Ventura A; Drilon A; Cocco E
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
    Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT; Bindal S; Najjar MK; Zhuang C; Khan M; Arrigo ABJ; Gonzalez AO; Zhang XR; Zhu JJ; Watabe K; Lo HW
    Cancer Lett; 2024 Aug; 597():217023. PubMed ID: 38852701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel indazole derivatives as second-generation TRK inhibitors.
    Qin Q; Lu S; Guo Z; Li Z; Fu Q; Wang X; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Oct; 276():116640. PubMed ID: 39033612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
    Zhang W; Tian S; Li X; Chen Y; Wang X; Zhang Y; Lv L; Li Y; Shi H; Bai C
    Clin Lung Cancer; 2024 May; 25(3):215-224.e3. PubMed ID: 38584068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With
    Hanf D; Heining C; Laaber K; Nebelung H; Uhrig S; Hutter B; Jahn A; Richter D; Aust D; Herbst F; Fröhling S; Glimm H; Folprecht G
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250401
    [No Abstract]   [Full Text] [Related]  

  • 14. Poor outcome in congenital mesoblastic nephroma with
    Sun M; Chen J; Xue Y; Deng Y; Van Mater D; Hiemcke-Jiwa LS; Wu P; Fang Y
    Transl Pediatr; 2024 Jun; 13(6):976-986. PubMed ID: 38984028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblastic orbital tumour with NTRK1 fusion transcript: when TRK inhibitors rescue surgery.
    Nahon-Estève S; Orbach D; Le Loarer F; Hofman P; Lassalle S
    Can J Ophthalmol; 2024 Aug; 59(4):e407-e409. PubMed ID: 38096907
    [No Abstract]   [Full Text] [Related]  

  • 16. LMNA::NTRK1 Fusion-positive Leiomyosarcoma: Discrepancy between DNA-based Comprehensive Genomic Profiling and RNA Sequencing.
    Suzuki N; Idogawa M; Emori M; Murase K; Arihara Y; Nakamura H; Usami M; Kubo T; Kinoshita I; Sugita S; Tokino T; Hasegawa T; Sakurai A; Takada K
    Intern Med; 2024 Aug; 63(15):2215-2219. PubMed ID: 38104989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelioid cell histiocytoma associated with IRF2BP2::NTRK1 fusion.
    Wood BA; Carr U; Van Vliet C; Mesbah Ardakani N
    Pathology; 2024 Aug; 56(5):743-746. PubMed ID: 38480049
    [No Abstract]   [Full Text] [Related]  

  • 18. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes.
    Wang H; Diaz AK; Shaw TI; Li Y; Niu M; Cho JH; Paugh BS; Zhang Y; Sifford J; Bai B; Wu Z; Tan H; Zhou S; Hover LD; Tillman HS; Shirinifard A; Thiagarajan S; Sablauer A; Pagala V; High AA; Wang X; Li C; Baker SJ; Peng J
    Nat Commun; 2019 Aug; 10(1):3718. PubMed ID: 31420543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to comment on "Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications".
    Krebs MG; Bennett I
    ESMO Open; 2021 Dec; 6(6):100307. PubMed ID: 34794056
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a
    Cerretti G; Padovan M; Guerriero A; Maccari M; Bosio A; Caccese M; Cella E; Pintacuda G; Librizzi G; Lombardi G
    Neurooncol Adv; 2024; 6(1):vdae077. PubMed ID: 38845690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.